Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$86.53 USD

86.53
1,558,811

+8.37 (10.71%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $86.53 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Hold on to Medidata (MDSO) Stock Now

by Zacks Equity Research

Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.

3 Reasons Growth Investors Will Love Haemonetics (HAE)

by Zacks Equity Research

Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here's Why You Should Bet on Merit Medical (MMSI) Stock Now

by Zacks Equity Research

Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.

Here's Why You Should Consider Betting On CONMED Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and continued focus on R&D.

ABIOMED Gets FDA Confirmation of the Safety of Impella RP

by Zacks Equity Research

ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump.

Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring

by Zacks Equity Research

Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.

Here's Why You Should Retain Cooper Companies (COO) Stock

by Zacks Equity Research

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex volatility remains a concern.

3 Reasons Why Haemonetics (HAE) Is a Great Growth Stock

by Zacks Equity Research

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

Here's Why You Should Retain DaVita (DVA) in Your Portfolio

by Zacks Equity Research

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from its core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up

by Zacks Equity Research

A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results

Haemonetics (HAE) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 10.91% and -0.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Haemonetics' Plasma Unit Grows, Global Expansion on Track

by Zacks Equity Research

Haemonetics' (HAE) Plasma arm steadily witnesses solid growth in the fiscal third quarter on 16% revenue rise at constant currency.

Why Is Haemonetics (HAE) Down 1.4% Since Last Earnings Report?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3

by Zacks Equity Research

Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.

Haemonetics (HAE) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 6.78% and -1.14%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Perrigo Stock Up as Appeal Date for Irish Tax Bill Nears

by Zacks Equity Research

Perrigo's (PRGO) shares rebound as the time to file an appeal against the Irish tax bill of $1.9 billion nears its deadline of Dec 28.

Perrigo Plunges on $1.9B Tax Bill From Irish Government

by Zacks Equity Research

Perrigo (PRGO), in a SEC filing, reports a $1.9 billion tax bill from Irish revenue department related to its subsidiary, Elan Pharma.

Here's Why You Should Buy Haemonetics (HAE) Stock Right Now

by Zacks Equity Research

Haemonetics (HAE) continues to witness strong growth in Plasma franchise.

Haemonetics (HAE) Down 8.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should iShares Morningstar Small-Cap ETF (JKJ) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JKJ

Haemonetics Strong on Plasma & Hemostasis Management Units

by Zacks Equity Research

Haemonetics (HAE) sees encouraging growth at the North America Plasma revenues on strong disposables along with growing software revenues.

Haemonetics (HAE) Earnings & Revenues Beat Estimates in Q2

by Zacks Equity Research

Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.